Semaglutide + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Overweight

Conditions

Overweight, Obesity

Trial Timeline

Sep 15, 2023 → May 7, 2025

NCT ID

NCT06041217

About Semaglutide + Placebo

Semaglutide + Placebo is a phase 3 stage product being developed by Novo Nordisk for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT06041217. Target conditions include Overweight, Obesity.

What happened to similar drugs?

0 of 20 similar drugs in Overweight were approved

Approved (0) Terminated (0) Active (20)

🔄Eloralintide + PlaceboEli LillyPhase 3

🔄Tirzepatide + PlaceboEli LillyPhase 3

🔄Maridebart cafraglutide + PlaceboAmgenPhase 3

🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

🔄Semaglutide + Placebo (semaglutide) + Liraglutide + Placebo (liraglutide)Novo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06041217	Phase 3	Completed	Sep 15, 2023	May 7, 2025	Overweight
NCT05726227	Phase 3	Active	Jul 7, 2023	Dec 7, 2026	Obesity
NCT05891496	Phase 3	Completed	Jun 20, 2023	Sep 8, 2025	Alzheimers Disease
NCT05486065	Phase 2	Completed	Aug 8, 2022	Dec 13, 2023	Diabetes Mellitus, Type 2
NCT04889183	Phase 3	Completed	Mar 14, 2022	May 28, 2024	Obesity
NCT04979130	Approved	Completed	Jan 1, 2022	Oct 16, 2024	Type 2 Diabetes
NCT04822181	Phase 3	Active	Apr 1, 2021	Apr 25, 2029	Non-alcoholic Steatohepatitis
NCT03842202	Phase 1	Completed	Feb 15, 2019	Nov 4, 2019	Overweight
NCT03548987	Phase 3	Completed	Jun 4, 2018	Mar 20, 2020	Metabolism and Nutrition Disorder
NCT03357380	Phase 1	Completed	Nov 28, 2017	Mar 20, 2020	Hepatobiliary Disorders
NCT03086330	Phase 3	Completed	Mar 15, 2017	Aug 6, 2018	Diabetes
NCT02692716	Phase 3	Completed	Jan 17, 2017	Sep 25, 2018	Diabetes
NCT02970942	Phase 2	Completed	Nov 30, 2016	Mar 19, 2020	Hepatobiliary Disorders
NCT02906930	Phase 3	Completed	Sep 20, 2016	Dec 8, 2017	Diabetes
NCT02827708	Phase 3	Completed	Sep 20, 2016	May 15, 2018	Diabetes
NCT02773381	Phase 1	Completed	Jun 2, 2016	Oct 19, 2018	Diabetes
NCT02557620	Phase 1	Completed	Sep 1, 2015	Apr 1, 2016	Diabetes
NCT02305381	Phase 3	Completed	Dec 1, 2014	Nov 21, 2015	Diabetes
NCT02212067	Phase 1	Completed	Aug 11, 2014	May 11, 2015	Diabetes
NCT02161588	Phase 1	Completed	Jun 1, 2014	Nov 1, 2014	Diabetes

Competing Products

20 competing products in Overweight

See all competitors

Product	Company	Stage	Hype Score
TERN-601	Terns Pharmaceuticals	Phase 2	32
LY3457263 + Tirzepatide + Placebo	Eli Lilly	Phase 1	29
LY3305677 + Placebo	Eli Lilly	Phase 1	29
LY3537031 + Placebo	Eli Lilly	Phase 1	33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)	Eli Lilly	Phase 2	42
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY4064912 + LY4064912 + Placebo + Placebo	Eli Lilly	Phase 1	36
LY3437943 + Ethinyl Estradiol + Drospirenone	Eli Lilly	Phase 1	29
Tirzepatide + Acetaminophen	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 2	39
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY3437943 + Placebo	Eli Lilly	Phase 1	29
LY3502970 + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	44
Eloralintide and Tirzepatide + Eloralintide	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
LY3541105 + Placebo	Eli Lilly	Phase 1	29
Retatrutide + Placebo	Eli Lilly	Phase 2	35
LY4167586 + Placebo + LY4167586	Eli Lilly	Phase 1	36
AZD9550 + AZD6234 + Placebo comparator	AstraZeneca	Phase 2	39